作者
Seth Heldenbrand, Chenghui Li, Rosemary P Cross, Kelly A DePiero, Travis B Dick, Kara Ferguson, Miae Kim, Erin Newkirk, Jeong M Park, Janice SudariaKerr, Eric M Tichy, Kimi R Ueda, Renee Weng, Jesse Wisniewski, Steven Gabardi
发表日期
2016/12
期刊
Transplant Infectious Disease
卷号
18
期号
6
页码范围
904-912
简介
Background
The cytomegalovirus (CMV) donorpositive/recipientpositive (D+/R+) population is the largest proportion of renal transplant recipients (RTR). Guidelines for prevention of CMV in the intermediaterisk D+/R+ population include prophylaxis with valganciclovir (VGCV) 900 mg/day for 3 months. This study is the first headtohead analysis, to our knowledge, comparing the efficacy and safety CMV prophylaxis of VGCV 450 vs 900 mg/day for 3 months in D+/R+ RTR.
Methods
A multicenter, retrospective analysis evaluated 478 adult RTR between January 2008 and October 2011. Study participants received VGCV 450 mg/day (Group 1; n=398) or 900 mg/day (Group 2; n=89)×3 months for CMV prophylaxis. All VGCV was adjusted for renal function. All groups included in this study received studyapproved induction and maintenance immunosuppression regimens. The primary endpoint was incidence of …
学术搜索中的文章
S Heldenbrand, C Li, RP Cross, KA DePiero, TB Dick… - Transplant Infectious Disease, 2016